
Sign up to save your podcasts
Or


Hey! Down Round is running a sale on premium membership. Sign up in the next week using this link, and you can get an annual membership for $49 instead of the usual $70.
This week we're talking about the much-hyped weight loss drug Ozempic and its producer, Danish pharma giant Novo Nordisk. Thanks to the crazy success of Ozempic, Novo Nordisk is now literally the biggest company in Europe by market cap. Now the vultures are circling, and a whole bunch of drugmakers are rushing competitors to market.
We talk about the drug, the company, it's weirdly 'techy' marketing and where it fits into the incoming universe of biotech and pharma tech.
Links
See omnystudio.com/listener for privacy information.
By Down Round4.8
99 ratings
Hey! Down Round is running a sale on premium membership. Sign up in the next week using this link, and you can get an annual membership for $49 instead of the usual $70.
This week we're talking about the much-hyped weight loss drug Ozempic and its producer, Danish pharma giant Novo Nordisk. Thanks to the crazy success of Ozempic, Novo Nordisk is now literally the biggest company in Europe by market cap. Now the vultures are circling, and a whole bunch of drugmakers are rushing competitors to market.
We talk about the drug, the company, it's weirdly 'techy' marketing and where it fits into the incoming universe of biotech and pharma tech.
Links
See omnystudio.com/listener for privacy information.

1,890 Listeners

8,839 Listeners

260 Listeners

585 Listeners

253 Listeners

560 Listeners

262 Listeners

934 Listeners

292 Listeners

550 Listeners

18 Listeners

18 Listeners

294 Listeners

204 Listeners

110 Listeners